Pacira BioSciences, Inc. (NASDAQ: PCRX) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.5B. The Maz Rating grades it against the other companies in its sector.
Pacira BioSciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $36.48, Pacira BioSciences, Inc. trades at 38.3x trailing earnings, 2.0x sales and 2.0x book value, with an EV/EBITDA of 11.8. Over the last twelve months it generated about $743M of revenue and $38M of net income. It runs a gross margin of 78.7%, an operating margin of 4.6% and a net margin of 5.1%. It shows return on equity of 5.5%, return on invested capital of 3.2% and a free cash flow yield of 11.6%. On the balance sheet: a debt-to-equity ratio of 0.48 and a current ratio of 4.68. Over the past 52 weeks the share price ranged from $18.80 to $36.67, with a beta of 0.25.
Pacira BioSciences, Inc. does not currently pay a dividend.
36 Wall Street analyst ratings cover the stock: 11 Buy, 22 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Pacira BioSciences, Inc. (PCRX) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 24.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 24.9% / 30% · Interest income / Revenue 1.41% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 24.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.9% / 33% · Receivables / Mkt Cap (36m) 10.4% / 49% · Interest income / Revenue 1.41% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 24.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.9% / 33.33% · Receivables / Mkt Cap (24m) 10.4% / 33.33% · Interest income / Revenue 1.41% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 29.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 20.1% / 33.33% · Receivables / Avg Assets (4Q) 10.3% / 33.33% · Interest income / Revenue 1.41% / 5% | Pass |
| FTSE | Debt / Total Assets 24.4% / 33.33% · (Cash+ST Inv) / Total Assets 24.6% / 33.33% · (Cash+Recv) / Total Assets 34.8% / 33.33% · Interest income / Revenue 1.41% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Pacira BioSciences, Inc. (PCRX) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Pacira BioSciences, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.41% of each dividend: Pacira BioSciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.